Acurx Pharmaceuticals (ACXP) Common Equity (2020 - 2026)

Acurx Pharmaceuticals (ACXP) has reported Common Equity for 7 consecutive years, with $8.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity rose 128.58% year-over-year to $8.2 million; the trailing twelve-month figure through Jun 2026 stood at $8.2 million (up 128.58% YoY), and the FY2025 full-year result was $5.3 million, up 756.51% from the prior year.
• Common Equity improved to $8.2 million in Q2 2026 per ACXP's latest filing, from $7.0 million in the prior quarter.
• Across five years, Common Equity topped out at $10.7 million in Q1 2022 and bottomed at $615121.0 in Q4 2024.
• Historically, Common Equity has averaged $5.5 million across 5 years, with a median of $5.3 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Common Equity slumped 86.82% in 2024, then surged 756.51% in 2025.
• Over 5 years, Common Equity stood at $7.3 million in 2022, then plunged by 36.2% to $4.7 million in 2023, then plunged by 86.82% to $615121.0 in 2024, then soared by 756.51% to $5.3 million in 2025, then soared by 54.73% to $8.2 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $8.2 million, $7.0 million, and $5.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.